title: Stage II seminomas and nonseminomas.
abstract: Although a rare presentation for testicular germ cell tumors, the optimal management for stage II disease generates considerable debate, which is, in large part, because of the potential curative role of single-modality treatment in many patients and overall excellent survival in those who require salvage treatment. Individualizing the treatment of each patient to ensure cure with minimal toxicity is challenging, given the rudimentary tools available for predicting disease relapse after initial therapy. Long-term toxicity and patient choice should be taken into account when selecting the management options.
authors.affiliation: Princess Margaret Hospital, 610 University Avenue, Toronto, ON M5G 2M9, Canada. peter.chung@rmp.uhn.on.ca
authors.forename: Peter W M
authors.initials: PW
authors.lastname: Chung
authors.forename: Philippe
authors.initials: P
authors.lastname: Bedard
mesh_terms: D017024:Chemotherapy, Adjuvant; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D009919:Orchiectomy; D018714:Radiotherapy, Adjuvant; D018239:Seminoma / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D013736:Testicular Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy